# Brainstem Raphe Echogenicity and Insomnia in Type 2 Diabetes: An Exploratory Cross-Sectional Study

**Authors:** Maarja Randväli, Kaja Mädamürk, Jekaterina Šteinmiller, Toomas Toomsoo

PMC · DOI: 10.3390/life16020298 · 2026-02-09

## TL;DR

This study explores the link between brainstem raphe echogenicity and insomnia in people with type 2 diabetes, finding a potential but not robust association.

## Contribution

The study introduces a novel exploratory analysis linking brainstem imaging findings with sleep symptoms in type 2 diabetes.

## Key findings

- Raphe hypoechogenicity was associated with higher insomnia scores before adjustment.
- No significant associations were found with depressive or anxiety symptoms.
- Participants with hypoechogenic raphe had higher prevalence of diabetes-related complications.

## Abstract

Background: Type 2 diabetes mellitus (T2DM) is associated with increased vulnerability to depression and other affective disturbances, potentially mediated by neurobiological alterations in the serotonergic brainstem raphe nuclei. This study examined whether raphe hypoechogenicity, assessed by transcranial sonography, is associated with depressive, anxiety, and sleep-related symptoms in individuals with T2DM, and whether such alterations are linked to diabetes-related complications. Methods: This cross-sectional study included 230 participants with T2DM and non-diabetic controls. Raphe echogenicity was assessed using transcranial sonography (TCS), and mental health outcomes were measured with the Patient Health Questionnaire 9 (PHQ-9) and the Emotional Well-Being Questionnaire (EWQ). To address demographic imbalance, analyses were repeated in a propensity score–adjusted subsample (n = 89). Results: Raphe hypoechogenicity was associated with higher insomnia scores (EWQ6; β = 0.67, p = 0.01); however, this association was attenuated to non-significance after adjustment for sleep medication use and did not survive correction for multiple comparisons, and no associations were observed with PHQ-9 or other EWQ subscales. The participants with hypoechogenic raphe also exhibited a higher prevalence of other diabetes-related complications (32% vs. 7%, p = 0.03). Conclusions: In this exploratory cross-sectional sample, reduced raphe echogenicity was not associated with overall depressive or anxiety symptom severity, but was associated with higher self-reported sleep-related symptom burden. However, this association was not robust to adjustment for sleep medication use or to correction for multiple comparisons. These findings are hypothesis-generating and require replication in larger, longitudinal and medication-naive cohorts using standardized sleep instruments.

## Linked entities

- **Diseases:** Type 2 diabetes mellitus (MONDO:0005148), depression (MONDO:0002050), anxiety (MONDO:0005618), insomnia (MONDO:0013600)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** type 1 diabetes (MESH:D003922), asthenia or mental exhaustion (MESH:D006359), glymphatic dysfunction (MESH:D006331), Obstructive sleep apnea (MESH:D020181), T2D (MESH:D003924), thyroid dysfunction (MESH:D013959), underweight (MESH:D013851), heart failure (MESH:D006333), Depressive (MESH:D003866), nephropathy (MESH:D007674), neuropathy (MESH:D009422), cognitive disorders (MESH:D003072), foot complications (MESH:D005534), illness (MESH:D002908), infectious diseases (MESH:D003141), multiple sclerosis (MESH:D009103), migraine (MESH:D008881), Sleep apnea (MESH:D012891), panic disorder (MESH:D016584), hypertension (MESH:D006973), anemia (MESH:D000740), epilepsy (MESH:D004827), gliosis (MESH:D005911), ulcers (MESH:D014456), osteoporosis (MESH:D010024), rheumatologic disorders (MESH:D012216), Mental health disorders (OMIM:603663), insulin resistance (MESH:D007333), myocardial infarction (MESH:D009203), hypoglycemia (MESH:D007003), fibromyalgia (MESH:D005356), ischemic disease (MESH:D017202), Fatigue (MESH:D005221), sleep-related symptom (MESH:D020183), overweight (MESH:D050177), retinopathy (MESH:D058437), stroke (MESH:D020521), affective disorders (MESH:D019964), arrhythmias (MESH:D001145), neurological diseases (MESH:D020271), obese (MESH:D009765), anxiety disorders (MESH:D001008), emotional difficulties (MESH:D051346), neurological disorders (MESH:D009461), MDD (MESH:D003865), metabolic disorder (MESH:D008659), Poor sleep impairs executive function (MESH:D012893), dyslipidemia (MESH:D050171), Parkinson's disease (MESH:D010300), injury to (MESH:D014947), Complications (MESH:D008107), inflammation (MESH:D007249), central nervous system (CNS) damage (MESH:D002493), asthma (MESH:D001249), neuroinflammatory (MESH:D000090862), anxiety (MESH:D001007), Mental Disorders (MESH:D001523), Insomnia (MESH:D007319), Diabetes (MESH:D003920)
- **Chemicals:** glucose (MESH:D005947), blood glucose (MESH:D001786)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942166/full.md

---
Source: https://tomesphere.com/paper/PMC12942166